Discrimination between the physiological cleavage fragments of fibrinogen and fibrin offers an approach to differentiation between fibrinogenolytic processes and fibrinolysis after coagulation. By use of the cleavage-associated neoantigen of fibrinogen (fg-Dneo) as a molecular marker, characteristic differences between the D regions of fibrinogen derivatives and fibrin derivatives can be demonstrated. The expression of fg-Dneo by X, Y., D: E complex, and D-fragments of fibrinogen or fibrin is shown to be quantitative and unitary. Characteristic differences between fg-Dneo sites present on fibrinogen cleavage fragments, as contrasted to fibrin cleavage fragments, are indicated by different competitive inhibition slopes, and appear to reflect differential binding affinity of selected anti-fg-Dneo antibodies for the specific molecular site. There is a linear relationship between the slope of quantitative competitive inhibition and the relative molar ratio of fibrinogen and fibrin derivatives. Identical immunochemical expressions are observed in vitro and in vivo, and support the thesis that cleavage in vivo is produced by plasmin. The differential immunochemical features of fg-Dneo expression may be the result of stable conformational and/or subtle structural differences between the D region of fibrinogen and fibrin cleavage fragments and suggest that precise changes in the D region are associated with the fibrin transition. These molecular features not only provide additional insight into the molecular immunology and structure of fibrinogen, but also appear to offer a new molecular approach to discrimination between fibrinogenolytic mechanisms as contrasted to fibrinolysis secondary to coagulation.
Conversion of fibrinogen to fibrin by thrombin (EC 3.4.4.13), the fibrin transition, is the culmination of the coagulation system, a central theme in hemostatic balance, and a commonly invoked pathogenetic mechanism (1) . Cleavage of fibrin by plasmin (EC 3.4.4.14), fibrinolysis, is intrinsic to maintenance of the hemostatic balance and leads to a generic series of polypeptide fragments possessing multiple pathophysiologic activities (2, 3) . Plasmin may also cleave fibrinogen directly (fibrinogenolysis), leading to a series of fragments generically similar to those generated from fibrin (4) . Although fibrinogen and fibrin differ strikingly in physicochemical behavior, the fibrin transition is associated with only a 2% loss of mass. This finding suggests that the physicochemical and pathophysiological properties of fibrin may result from conformational changes in the molecule. Such conAbbreviations: X, Y, D, E, and D:E complex, defined plasmin cleavage fragments of fibrinogen/fibrin; fg-, fibrinogen-derived plasmin cleavage fragments; fb-, fibrin-derived plasmin cleavage fragments; fg-Dne., cleavage-associated neoantigen of fibrinogen. 1169
formational differences may lead to both structural and conformational differences between the plasmin cleavage derivatives of fibrinogen and fibrin. Although only minor or equivocal biochemical differences between fibrin and fibrinogen cleavage fragments have been suggested (5, 6 ), specific and systematic major differences have not been defined.
In this work, we have compared the quantitative and qualitative molecular expressions of fibrin and fibrinogen cleavage fragments with respect to a specific marker, the cleavage-associated neoantigen, fg-Dneo (7, 8) . We have shown (9) that this antigenically recognizable molecular site is expressed in an equimolar fashion by X, Y, D E complex, and D-fragments of fibrinogen, but not by fibrinogen itself. We now demonstrated that the fg-Dneo site is also expressed by the comparable fibrin derivatives in vitro and in vivo, and this molecular site is expressed in a characteristically different fashion by fibrin derivatives. This immunochemical difference in fg-Dneo expression suggests characteristic and stable conformational or minor structural differences between the D regions of fibrinogen and fibrin derivatives, and offers a molecular approach to the recognition and differentiation of fibrinogenolytic from fibrinolytic processes and their associated disease states.
MATERIALS AND METHODS
Fibrinogen was purified from human plasma by sequential fractionation with cold ethanol and with ammonium sulfate (7, 10) . Fibrin was prepared from purified fibrinogen (98% coagulable); 10 units of bovine thrombin (Parke, Davis & Co., Detroit, Mich.) was added per mg of fibrinogen (2 mg/ml), in the presence of 0.02 M EDTA to prevent crosslinking by Factor XIII. Coagulation was done at 40 to facilitate uniform inclusion of plasmin directly into the fibrin clot, while inhibiting plasmin activity. Both fibrin and fibrinogen were digested at 370 with urokinase-activated plasmin (Cutter Laboratories, Berkeley, Calif.). At various intervals, aliquots were withdrawn, 0.02 M e-aminocaproic acid was added, and the digests were applied to a 2.5 X 90 cm A-1.5 Agarose column equilibrated with 1.0 M NaCl-0.04 M e-aminocaproic acid-0.01 M Tris * HCl (pH 8.0). Protein peaks corresponding to the X-and Y-fragments, and the D: E complex were recovered in the column effluent of both fibrinogen and fibrin digests (9) . These species were then recycled separately on the same column to insure purity. D E complex fractions were separated into constituent D-and E-fragments by DEAE-cellulose chromatography (11) . Each of the purified fragments appeared and that the neoantigenic sites present in the intact fibrinogen molecule were not exposed by iodide. Patient plasmas used in this study and the criteria for diagnosis of disseminated intravascular coagulation have been described (9) .
RESULTS
Differential expression of the fg-Dne. site by fibrin, as con- Table 2 it is observed that fb-X, fb-Y, and fb-D:E express fg-Dneo in a qualitatively and quantitatively similar manner as fb-D. Competitive inhibition slopes are comparable, quantitative inhibitions are similar, and fg-Dneo expression, as compared with fb-D, is about equal to 1. The parent fibrin molecule solubilized in KI and fb-E exhibited no fg-Dneo expression. The mean slope for all fibrinogen-derived fragments is 0.207 + 0.003, as contrasted to 0.340 i 0.001 for all fibrinderived fragments. While the slope variations within each family of fragments are minimal, the difference between the two sets of fragments appears to be highly significant. The relative molar expression of fg-Dneo by fibrin fragments of 0.91 4 0.10 is comparable to the value of 0.92 + 0.16 for all fibrinogen fragments. Variations from unity are noted specifically for the Y-fragments and the D: E complexes, with both the fibrin and fibrinogen analogues exhibiting similar deviations from the anticipated value. This result may be due to the complete lack of fg-Dneo expression by minor subpopulations of these fragments, to consistent errors in the determination of protein concentrations, or to minor inaccuracies in the published molecular weights. Fig. 2 demonstrates that these differences in competitive binding affinity of fibrin and fibrinogen cleavage fragments do not arise artifactually during isolation of the fragments. Fresh plasma samples were used to simulate: (a) fibrinolysis by clotting with thrombin and cleaving with plasmin; and (b) fibrinogenolysis by cleaving directly with plasmin. Immunochemical expression of fg-Dneo by fibrinolytic, fibrinogenolytic, and control plasmas was assayed. The fibrinolytic plasma is clearly distinguished from the fibrinogenolytic plasma on the basis of their inhibition profiles (Fig. 2) . The slope of 0.206 for the fibrinogenolytic plasma and 0.342 for the fibrinolytic plasma are consistent with the slopes obtained with the isolated and purified fibrinogen derivatives (0.207) and fibrin derivatives (0.340), respectively.
Although fibrinogenolysis and fibrinolysis are conceptually distinct pathological processes, one event does not preclude the other, and both might occur simultaneously in vivo. If differences in competitive binding affinity are to provide an effective means for discriminating fibrin from fibrinogen cleavage products, fragments of either molecular origin should contribute to the observed competitive inhibition slope in proportion to their concentration. Mixtures of fg-D and fb-D at known molar concentrations were assayed and the slopes of the competitive inhibition profiles were measured. Fig. 3 illustrates that the competitive inhibition slopes exhibit a linear dependence on the relative proportion of fb-D and fg-D. This result not only indicates that the proportion of fibrin and fibrinogen fragments in a mixture of unknown molecular origin may be determined, but also that the molar concentration of fibrin and fibrinogen-derived fragments may be calculated (see Appendix).
The differential expressions of fg-Dneo characteristic of fibrinogen and fibrin cleavage fragments are also observed in vivo, as shown in Table 3 . Plasmas from patients with diseases commonly associated with the presence of circulating fibrinogen/fibrin cleavage fragments, and in which noncoagulable cleavage fragments were demonstrable by radial immunodiffusion assay (9, 14) , were all positive for fg-Dneo by radio This study demonstrates that, although a specific neoantigenic site may be quantitatively expressed by cleavage derivatives of two different forms of a molecule, the. affinity of a specific antiserum may vary for one form as contrasted to the other form. Thus, the fg-Dn. site appears to be differentially expressed by the derivatives of fibrin and fibrinogen. This differential expression cannot be attributed to partial expression of a composite of fg-Dne. determinants by one family of fragments, since derivatives of both fibrinogen and fibrin are capable of complete neutralization of anti-fg-Dne. antibody. Furthermore, these differences presumably cannot be due to major differences in secondary structure resulting from differential plasmin cleavage of fibrin or fibrinogen, since the derivative fragments appear to be similar in size and aminoacid composition (4, 5) . Thus, the specific differential expression of fg-D... must reflect conformational or very minor structural differences in the neoantigenic site per se or in the immediate vicinity of this site. These conformational or minor structural differences in the fg-Dneo locus are influenced by the conversion of fibrinogen to fibrin. Although the fibrin transition does not directly expose the fg-Dneo site, it does apparently control the subsequent exposure and immunochemical characteristics of this region. This finding suggests that cleavage by thrombin of fibrinopeptides from the amino-terminal aspect of fibrinogen is associated with conformational changes in more distant regions of the molecule, changes that may influence biological expressions of the physiological catabolic fragments.
Plasma from subjects with various diseases associated with pathologic cleavage in vivo contained the cleavage-associated neoantigen, fg-D... Competitive inhibition profiles characteristic of fibrin derivatives were observed in the plasma from some individuals, whereas only fibrinogen cleavage fragments were recognized in the plasma of another subject. The fibrin derivative-containing plasmas appear to reflect fibrinolysis after in vivo coagulation, whereas the fibrinogen derivative containing plasma appears to reflect primary fibrinogenolysis. Plasma from other subjects exhibited competitive inhibition slopes in fg-Dneo assays that were intermediate to the fb-D and fg-D standards. We demonstrated that such slopes may arise from mixtures of fibrin derivatives and fibrinogen derivatives. Other enzymes may cleave fibrinogen in vitro, and possibly in vivo, but assay of the fg-Dneo expression generated by other enzymes-such as leukocyte proteases-have yielded slopes distinctly different from plasmin cleavage (8, 9 ) that cannot directly account for the results observed in this study.
It may be significant that anti-fg-Dn,0 antiserum derived from the early phase of the immune response and used in this study was capable of discriminating between the cleavage fragments of fibrinogen and fibrin. During the later phases of this same immune response, no such discrimination was observed (9) . It is well known that the binding affinity of antibody is low early in the immune response (16) . These preliminary observations suggest that the capacity to recognize conformational differences may be dependent upon early, lowaffinity antibody rather than a difference in antigenic specificity.
The present study not only introduces evidence for discrete molecular differences between the products of fibrinogenolysis and fibrinolysis, but also provides a highly sensitive and precise approach to the recognition of the products of these processes in vivo and in vitro. The fraction of cleavage fragments derived from fibrinogen, Fg,, is given by: Fgx = (1-Fbx) [2] The molar concentration of fragments in the unknown is then determined from the concentration required for 50% competitive inhibition. Since the observed molar concentration of the unknown will be influenced by the relative proportion of fibrin and fibrinogen fragments, a factor, C.F., must 
